ID   NF2L2_HUMAN             Reviewed;         605 AA.
AC   Q16236; B2RBU2; B4E338; E9PGJ7; Q53RW6; Q59HH2; Q96F71;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2002, sequence version 3.
DT   18-JUN-2025, entry version 226.
DE   RecName: Full=Nuclear factor erythroid 2-related factor 2 {ECO:0000303|PubMed:11035812};
DE            Short=NF-E2-related factor 2 {ECO:0000303|PubMed:11035812};
DE            Short=NFE2-related factor 2 {ECO:0000303|PubMed:11035812};
DE            Short=Nrf-2 {ECO:0000303|PubMed:11256947};
DE   AltName: Full=Nuclear factor, erythroid derived 2, like 2 {ECO:0000303|PubMed:33009401, ECO:0000303|PubMed:7937919};
GN   Name=NFE2L2 {ECO:0000303|PubMed:29018201, ECO:0000312|HGNC:HGNC:7782};
GN   Synonyms=NRF2 {ECO:0000303|PubMed:33009401,
GN   ECO:0000303|PubMed:7937919};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Tongue, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Myeloid leukemia cell;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-202 (ISOFORM 1).
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-605 (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal liver;
RX   PubMed=7937919; DOI=10.1073/pnas.91.21.9926;
RA   Moi P., Chan K., Asunis I., Cao A., Kan Y.W.;
RT   "Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine
RT   zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat
RT   of the beta-globin locus control region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9926-9930(1994).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY PKC.
RX   PubMed=11035812; DOI=10.1073/pnas.220418997;
RA   Huang H.-C., Nguyen T., Pickett C.B.;
RT   "Regulation of the antioxidant response element by protein kinase C-
RT   mediated phosphorylation of NF-E2-related factor 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12475-12480(2000).
RN   [9]
RP   INTERACTION WITH PMF1.
RX   PubMed=11256947; DOI=10.1042/0264-6021:3550045;
RA   Wang Y., Devereux W., Stewart T.M., Casero R.A. Jr.;
RT   "Characterization of the interaction between the transcription factors
RT   human polyamine modulated factor (PMF-1) and NF-E2-related factor 2 (Nrf-2)
RT   in the transcriptional regulation of the spermidine/spermine N1-
RT   acetyltransferase (SSAT) gene.";
RL   Biochem. J. 355:45-49(2001).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH KEAP1, UBIQUITINATION,
RP   ETGE MOTIF, DOMAIN, AND MUTAGENESIS OF 79-GLU--GLU-82 AND GLU-82.
RX   PubMed=15601839; DOI=10.1128/mcb.25.1.162-171.2005;
RA   Furukawa M., Xiong Y.;
RT   "BTB protein Keap1 targets antioxidant transcription factor Nrf2 for
RT   ubiquitination by the Cullin 3-Roc1 ligase.";
RL   Mol. Cell. Biol. 25:162-171(2005).
RN   [11]
RP   UBIQUITINATION.
RX   PubMed=15983046; DOI=10.1074/jbc.m501279200;
RA   Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M.;
RT   "Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3,
RT   targets Keap1 for degradation by a proteasome-independent pathway.";
RL   J. Biol. Chem. 280:30091-30099(2005).
RN   [12]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=19489739; DOI=10.1042/bj20090471;
RA   Eggler A.L., Small E., Hannink M., Mesecar A.D.;
RT   "Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE)
RT   activation are dependent on the partial molar volume at position 151 of
RT   Keap1.";
RL   Biochem. J. 422:171-180(2009).
RN   [13]
RP   INTERACTION WITH PGAM5 AND KEAP1.
RX   PubMed=18387606; DOI=10.1016/j.yexcr.2008.02.014;
RA   Lo S.-C., Hannink M.;
RT   "PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to
RT   mitochondria.";
RL   Exp. Cell Res. 314:1789-1803(2008).
RN   [14]
RP   INDUCTION.
RX   PubMed=19424503; DOI=10.1371/journal.pone.0005492;
RA   Wang X.J., Zhang D.D.;
RT   "Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational
RT   level.";
RL   PLoS ONE 4:E5492-E5492(2009).
RN   [15]
RP   FUNCTION.
RX   PubMed=20452972; DOI=10.1074/jbc.m110.118976;
RA   Jain A., Lamark T., Sjoettem E., Larsen K.B., Awuh J.A., Oevervatn A.,
RA   McMahon M., Hayes J.D., Johansen T.;
RT   "p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a
RT   positive feedback loop by inducing antioxidant response element-driven gene
RT   transcription.";
RL   J. Biol. Chem. 285:22576-22591(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INTERACTION WITH EEF1D.
RX   PubMed=21597468; DOI=10.1038/embor.2011.82;
RA   Kaitsuka T., Tomizawa K., Matsushita M.;
RT   "Transformation of eEF1Bdelta into heat-shock response transcription factor
RT   by alternative splicing.";
RL   EMBO Rep. 12:673-681(2011).
RN   [18]
RP   ACETYLATION AT LYS-596 AND LYS-599, DEACETYLATION BY SIRT1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21196497; DOI=10.1074/jbc.m110.208173;
RA   Kawai Y., Garduno L., Theodore M., Yang J., Arinze I.J.;
RT   "Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor
RT   erythroid 2-related factor 2) regulates its transcriptional activity and
RT   nucleocytoplasmic localization.";
RL   J. Biol. Chem. 286:7629-7640(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   INTERACTION WITH HERPES VIRUS 8 PROTEIN LANA1 (MICROBIAL INFECTION), AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=25995248; DOI=10.1128/jvi.00895-15;
RA   Gjyshi O., Roy A., Dutta S., Veettil M.V., Dutta D., Chandran B.;
RT   "Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus
RT   Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene
RT   Repression.";
RL   J. Virol. 89:7874-7892(2015).
RN   [21]
RP   INTERACTION WITH MOTS-C, AND SUBCELLULAR LOCATION.
RX   PubMed=29983246; DOI=10.1016/j.cmet.2018.06.008;
RA   Kim K.H., Son J.M., Benayoun B.A., Lee C.;
RT   "The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to
RT   Regulate Nuclear Gene Expression in Response to Metabolic Stress.";
RL   Cell Metab. 28:516-524(2018).
RN   [22]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=29590092; DOI=10.1038/nature25986;
RA   Mills E.L., Ryan D.G., Prag H.A., Dikovskaya D., Menon D., Zaslona Z.,
RA   Jedrychowski M.P., Costa A.S.H., Higgins M., Hams E., Szpyt J.,
RA   Runtsch M.C., King M.S., McGouran J.F., Fischer R., Kessler B.M.,
RA   McGettrick A.F., Hughes M.M., Carroll R.G., Booty L.M., Knatko E.V.,
RA   Meakin P.J., Ashford M.L.J., Modis L.K., Brunori G., Sevin D.C.,
RA   Fallon P.G., Caldwell S.T., Kunji E.R.S., Chouchani E.T., Frezza C.,
RA   Dinkova-Kostova A.T., Hartley R.C., Murphy M.P., O'Neill L.A.;
RT   "Itaconate is an anti-inflammatory metabolite that activates Nrf2 via
RT   alkylation of KEAP1.";
RL   Nature 556:113-117(2018).
RN   [23]
RP   FUNCTION, GLYCATION AT LYS-462; LYS-472; LYS-487; ARG-499; ARG-569 AND
RP   LYS-574, AND MUTAGENESIS OF LYS-462; LYS-472; LYS-487; ARG-499; ARG-569 AND
RP   ARG-587.
RX   PubMed=31398338; DOI=10.1016/j.cell.2019.07.031;
RA   Sanghvi V.R., Leibold J., Mina M., Mohan P., Berishaj M., Li Z.,
RA   Miele M.M., Lailler N., Zhao C., de Stanchina E., Viale A., Akkari L.,
RA   Lowe S.W., Ciriello G., Hendrickson R.C., Wendel H.G.;
RT   "The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-
RT   kinase.";
RL   Cell 178:807-819(2019).
RN   [24]
RP   REVIEW.
RX   PubMed=28842501; DOI=10.1074/jbc.r117.800169;
RA   Suzuki T., Yamamoto M.;
RT   "Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2
RT   system during cellular stress.";
RL   J. Biol. Chem. 292:16817-16824(2017).
RN   [25]
RP   FUNCTION.
RX   PubMed=30158636; DOI=10.1038/s41467-018-05861-7;
RA   Olagnier D., Brandtoft A.M., Gunderstofte C., Villadsen N.L., Krapp C.,
RA   Thielke A.L., Laustsen A., Peri S., Hansen A.L., Bonefeld L., Thyrsted J.,
RA   Bruun V., Iversen M.B., Lin L., Artegoitia V.M., Su C., Yang L., Lin R.,
RA   Balachandran S., Luo Y., Nyegaard M., Marrero B., Goldbach-Mansky R.,
RA   Motwani M., Ryan D.G., Fitzgerald K.A., O'Neill L.A., Hollensen A.K.,
RA   Damgaard C.K., de Paoli F.V., Bertram H.C., Jakobsen M.R., Poulsen T.B.,
RA   Holm C.K.;
RT   "Nrf2 negatively regulates STING indicating a link between antiviral
RT   sensing and metabolic reprogramming.";
RL   Nat. Commun. 9:3506-3506(2018).
RN   [26]
RP   FUNCTION, ACTIVITY REGULATION (MICROBIAL INFECTION), AND ACTIVITY
RP   REGULATION.
RX   PubMed=33009401; DOI=10.1038/s41467-020-18764-3;
RA   Olagnier D., Farahani E., Thyrsted J., Blay-Cadanet J., Herengt A.,
RA   Idorn M., Hait A., Hernaez B., Knudsen A., Iversen M.B., Schilling M.,
RA   Joergensen S.E., Thomsen M., Reinert L.S., Lappe M., Hoang H.D.,
RA   Gilchrist V.H., Hansen A.L., Ottosen R., Nielsen C.G., Moeller C.,
RA   van der Horst D., Peri S., Balachandran S., Huang J., Jakobsen M.,
RA   Svenningsen E.B., Poulsen T.B., Bartsch L., Thielke A.L., Luo Y., Alain T.,
RA   Rehwinkel J., Alcami A., Hiscott J., Mogensen T.H., Paludan S.R.,
RA   Holm C.K.;
RT   "SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral
RT   and anti-inflammatory activity of 4-octyl-itaconate and dimethyl
RT   fumarate.";
RL   Nat. Commun. 11:4938-4938(2020).
RN   [27]
RP   ERRATUM OF PUBMED:33009401.
RX   PubMed=33087717; DOI=10.1038/s41467-020-19363-y;
RA   Olagnier D., Farahani E., Thyrsted J., Blay-Cadanet J., Herengt A.,
RA   Idorn M., Hait A., Hernaez B., Knudsen A., Iversen M.B., Schilling M.,
RA   Joergensen S.E., Thomsen M., Reinert L.S., Lappe M., Hoang H.D.,
RA   Gilchrist V.H., Hansen A.L., Ottosen R., Nielsen C.G., Moeller C.,
RA   van der Horst D., Peri S., Balachandran S., Huang J., Jakobsen M.,
RA   Svenningsen E.B., Poulsen T.B., Bartsch L., Thielke A.L., Luo Y., Alain T.,
RA   Rehwinkel J., Alcami A., Hiscott J., Mogensen T.H., Paludan S.R.,
RA   Holm C.K.;
RT   "Author Correction: SARS-CoV2-mediated suppression of NRF2-signaling
RT   reveals potent antiviral and anti-inflammatory activity of 4-octyl-
RT   itaconate and dimethyl fumarate.";
RL   Nat. Commun. 11:5419-5419(2020).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 69-84 IN COMPLEX WITH KEAP1, AND
RP   MUTAGENESIS OF THR-80.
RX   PubMed=16888629; DOI=10.1038/sj.emboj.7601243;
RA   Lo S.-C., Li X., Henzl M.T., Beamer L.J., Hannink M.;
RT   "Structure of the Keap1:Nrf2 interface provides mechanistic insight into
RT   Nrf2 signaling.";
RL   EMBO J. 25:3605-3617(2006).
RN   [29]
RP   INVOLVEMENT IN IMDDHH, VARIANTS IMDDHH ARG-31; LYS-79; LYS-80 AND SER-81,
RP   CHARACTERIZATION OF VARIANT IMDDHH LYS-80, AND FUNCTION.
RX   PubMed=29018201; DOI=10.1038/s41467-017-00932-7;
RA   Huppke P., Weissbach S., Church J.A., Schnur R., Krusen M.,
RA   Dreha-Kulaczewski S., Kuehn-Velten W.N., Wolf A., Huppke B., Millan F.,
RA   Begtrup A., Almusafri F., Thiele H., Altmueller J., Nuernberg P.,
RA   Mueller M., Gaertner J.;
RT   "Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem
RT   disorder.";
RL   Nat. Commun. 8:818-818(2017).
CC   -!- FUNCTION: Transcription factor that plays a key role in the response to
CC       oxidative stress: binds to antioxidant response (ARE) elements present
CC       in the promoter region of many cytoprotective genes, such as phase 2
CC       detoxifying enzymes, and promotes their expression, thereby
CC       neutralizing reactive electrophiles (PubMed:11035812, PubMed:19489739,
CC       PubMed:29018201, PubMed:31398338). In normal conditions, ubiquitinated
CC       and degraded in the cytoplasm by the BCR(KEAP1) complex
CC       (PubMed:11035812, PubMed:15601839, PubMed:29018201). In response to
CC       oxidative stress, electrophile metabolites inhibit activity of the
CC       BCR(KEAP1) complex, promoting nuclear accumulation of NFE2L2/NRF2,
CC       heterodimerization with one of the small Maf proteins and binding to
CC       ARE elements of cytoprotective target genes (PubMed:19489739,
CC       PubMed:29590092). The NFE2L2/NRF2 pathway is also activated in response
CC       to selective autophagy: autophagy promotes interaction between KEAP1
CC       and SQSTM1/p62 and subsequent inactivation of the BCR(KEAP1) complex,
CC       leading to NFE2L2/NRF2 nuclear accumulation and expression of
CC       cytoprotective genes (PubMed:20452972). The NFE2L2/NRF2 pathway is also
CC       activated during the unfolded protein response (UPR), contributing to
CC       redox homeostasis and cell survival following endoplasmic reticulum
CC       stress (By similarity). May also be involved in the transcriptional
CC       activation of genes of the beta-globin cluster by mediating enhancer
CC       activity of hypersensitive site 2 of the beta-globin locus control
CC       region (PubMed:7937919). Also plays an important role in the regulation
CC       of the innate immune response and antiviral cytosolic DNA sensing. It
CC       is a critical regulator of the innate immune response and survival
CC       during sepsis by maintaining redox homeostasis and restraint of the
CC       dysregulation of pro-inflammatory signaling pathways like MyD88-
CC       dependent and -independent and TNF-alpha signaling (By similarity).
CC       Suppresses macrophage inflammatory response by blocking pro-
CC       inflammatory cytokine transcription and the induction of IL6 (By
CC       similarity). Binds to the proximity of pro-inflammatory genes in
CC       macrophages and inhibits RNA Pol II recruitment. The inhibition is
CC       independent of the NRF2-binding motif and reactive oxygen species level
CC       (By similarity). Represses antiviral cytosolic DNA sensing by
CC       suppressing the expression of the adapter protein STING1 and decreasing
CC       responsiveness to STING1 agonists while increasing susceptibility to
CC       infection with DNA viruses (PubMed:30158636). Once activated, limits
CC       the release of pro-inflammatory cytokines in response to human
CC       coronavirus SARS-CoV-2 infection and to virus-derived ligands through a
CC       mechanism that involves inhibition of IRF3 dimerization. Also inhibits
CC       both SARS-CoV-2 replication, as well as the replication of several
CC       other pathogenic viruses including Herpes Simplex Virus-1 and-2,
CC       Vaccinia virus, and Zika virus through a type I interferon (IFN)-
CC       independent mechanism (PubMed:33009401). {ECO:0000250|UniProtKB:Q60795,
CC       ECO:0000269|PubMed:11035812, ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:19489739, ECO:0000269|PubMed:20452972,
CC       ECO:0000269|PubMed:29018201, ECO:0000269|PubMed:29590092,
CC       ECO:0000269|PubMed:30158636, ECO:0000269|PubMed:31398338,
CC       ECO:0000269|PubMed:33009401, ECO:0000269|PubMed:7937919}.
CC   -!- ACTIVITY REGULATION: Activated by cell derived metabolites including
CC       itaconate and fumarate. {ECO:0000269|PubMed:29590092,
CC       ECO:0000269|PubMed:33009401}.
CC   -!- ACTIVITY REGULATION: (Microbial infection) Transcription factor
CC       activity on antioxidant target genes is significantly inhibited by SARS
CC       coronavirus-2/SARS-COV-2. {ECO:0000269|PubMed:29018201}.
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with small Maf proteins (By
CC       similarity). Interacts (via the bZIP domain) with MAFG and MAFK;
CC       required for binding to antioxidant response elements (AREs) on DNA (By
CC       similarity). Interacts with KEAP1; the interaction is direct and
CC       promotes ubiquitination by the BCR(KEAP1) E3 ubiquitin ligase complex
CC       (PubMed:15601839, PubMed:16888629). Forms a ternary complex with PGAM5
CC       and KEAP1 (PubMed:18387606). Interacts with EEF1D at heat shock
CC       promoter elements (HSE) (PubMed:21597468). Interacts via its leucine-
CC       zipper domain with the coiled-coil domain of PMF1 (PubMed:11256947).
CC       Interacts with CHD6; involved in activation of the transcription (By
CC       similarity). Interacts with ESRRB; represses NFE2L2 transcriptional
CC       activity (By similarity). Interacts with MOTS-c, a peptide produced by
CC       the mitochondrially encoded 12S rRNA MT-RNR1; the interaction occurs in
CC       the nucleus following metabolic stress (PubMed:29983246).
CC       {ECO:0000250|UniProtKB:O54968, ECO:0000250|UniProtKB:Q60795,
CC       ECO:0000269|PubMed:11256947, ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:18387606,
CC       ECO:0000269|PubMed:21597468, ECO:0000269|PubMed:29983246}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein
CC       LANA1. {ECO:0000269|PubMed:25995248}.
CC   -!- INTERACTION:
CC       Q16236; P27695: APEX1; NbExp=3; IntAct=EBI-2007911, EBI-1048805;
CC       Q16236; P53365: ARFIP2; NbExp=2; IntAct=EBI-2007911, EBI-638194;
CC       Q16236; O15144: ARPC2; NbExp=5; IntAct=EBI-2007911, EBI-352356;
CC       Q16236; P18847: ATF3; NbExp=5; IntAct=EBI-2007911, EBI-712767;
CC       Q16236; P18848: ATF4; NbExp=8; IntAct=EBI-2007911, EBI-492498;
CC       Q16236; Q9ULD4: BRPF3; NbExp=3; IntAct=EBI-2007911, EBI-1753470;
CC       Q16236; Q9Y297: BTRC; NbExp=2; IntAct=EBI-2007911, EBI-307461;
CC       Q16236; P55210: CASP7; NbExp=2; IntAct=EBI-2007911, EBI-523958;
CC       Q16236; P53567: CEBPG; NbExp=5; IntAct=EBI-2007911, EBI-740209;
CC       Q16236; Q96G23: CERS2; NbExp=2; IntAct=EBI-2007911, EBI-1057080;
CC       Q16236; Q6V702: CFAP299; NbExp=3; IntAct=EBI-2007911, EBI-25429087;
CC       Q16236; Q9UBW8: COPS7A; NbExp=2; IntAct=EBI-2007911, EBI-712982;
CC       Q16236; O60519: CREBL2; NbExp=5; IntAct=EBI-2007911, EBI-2872455;
CC       Q16236; Q9NS37: CREBZF; NbExp=5; IntAct=EBI-2007911, EBI-632965;
CC       Q16236; P35638: DDIT3; NbExp=5; IntAct=EBI-2007911, EBI-742651;
CC       Q16236; O75822: EIF3J; NbExp=5; IntAct=EBI-2007911, EBI-366647;
CC       Q16236; P78545: ELF3; NbExp=5; IntAct=EBI-2007911, EBI-1057285;
CC       Q16236; P19419: ELK1; NbExp=5; IntAct=EBI-2007911, EBI-726632;
CC       Q16236; P15036: ETS2; NbExp=2; IntAct=EBI-2007911, EBI-1646991;
CC       Q16236; P50549: ETV1; NbExp=4; IntAct=EBI-2007911, EBI-3905068;
CC       Q16236; P43268: ETV4; NbExp=6; IntAct=EBI-2007911, EBI-6447147;
CC       Q16236; P41212: ETV6; NbExp=5; IntAct=EBI-2007911, EBI-1372759;
CC       Q16236; Q9UKB1: FBXW11; NbExp=2; IntAct=EBI-2007911, EBI-355189;
CC       Q16236; P53539: FOSB; NbExp=6; IntAct=EBI-2007911, EBI-2806743;
CC       Q16236; P15408: FOSL2; NbExp=6; IntAct=EBI-2007911, EBI-3893419;
CC       Q16236; P15976: GATA1; NbExp=2; IntAct=EBI-2007911, EBI-3909284;
CC       Q16236; P62993: GRB2; NbExp=2; IntAct=EBI-2007911, EBI-401755;
CC       Q16236; P10914: IRF1; NbExp=3; IntAct=EBI-2007911, EBI-1055781;
CC       Q16236; P05412: JUN; NbExp=2; IntAct=EBI-2007911, EBI-852823;
CC       Q16236; O60341: KDM1A; NbExp=5; IntAct=EBI-2007911, EBI-710124;
CC       Q16236; Q14145: KEAP1; NbExp=39; IntAct=EBI-2007911, EBI-751001;
CC       Q16236; P52292: KPNA2; NbExp=4; IntAct=EBI-2007911, EBI-349938;
CC       Q16236; O00629: KPNA4; NbExp=4; IntAct=EBI-2007911, EBI-396343;
CC       Q16236; Q9UJU2: LEF1; NbExp=3; IntAct=EBI-2007911, EBI-926131;
CC       Q16236; Q9ULX9: MAFF; NbExp=6; IntAct=EBI-2007911, EBI-721128;
CC       Q16236; O15525: MAFG; NbExp=16; IntAct=EBI-2007911, EBI-713514;
CC       Q16236; O60675: MAFK; NbExp=7; IntAct=EBI-2007911, EBI-2559512;
CC       Q16236; P52564: MAP2K6; NbExp=5; IntAct=EBI-2007911, EBI-448135;
CC       Q16236; P41227: NAA10; NbExp=4; IntAct=EBI-2007911, EBI-747693;
CC       Q16236; O94916: NFAT5; NbExp=4; IntAct=EBI-2007911, EBI-308320;
CC       Q16236; Q13526: PIN1; NbExp=5; IntAct=EBI-2007911, EBI-714158;
CC       Q16236; Q6P1K2: PMF1; NbExp=2; IntAct=EBI-2007911, EBI-713832;
CC       Q16236; P10276: RARA; NbExp=2; IntAct=EBI-2007911, EBI-413374;
CC       Q16236; Q04864: REL; NbExp=5; IntAct=EBI-2007911, EBI-307352;
CC       Q16236; Q04206: RELA; NbExp=5; IntAct=EBI-2007911, EBI-73886;
CC       Q16236; Q13342: SP140; NbExp=4; IntAct=EBI-2007911, EBI-2865100;
CC       Q16236; P40763: STAT3; NbExp=5; IntAct=EBI-2007911, EBI-518675;
CC       Q16236; O75478: TADA2A; NbExp=2; IntAct=EBI-2007911, EBI-742268;
CC       Q16236; P20226: TBP; NbExp=5; IntAct=EBI-2007911, EBI-355371;
CC       Q16236; Q10587: TEF; NbExp=5; IntAct=EBI-2007911, EBI-2796967;
CC       Q16236; P13805: TNNT1; NbExp=4; IntAct=EBI-2007911, EBI-726527;
CC       Q16236; P13805-3: TNNT1; NbExp=3; IntAct=EBI-2007911, EBI-12151635;
CC       Q16236; Q9BTA9: WAC; NbExp=3; IntAct=EBI-2007911, EBI-749118;
CC       Q16236; Q60953: Pml; Xeno; NbExp=2; IntAct=EBI-2007911, EBI-3895605;
CC       Q16236; P11416: Rara; Xeno; NbExp=2; IntAct=EBI-2007911, EBI-346736;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:11035812,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497}. Nucleus
CC       {ECO:0000255|PROSITE-ProRule:PRU00978, ECO:0000269|PubMed:11035812,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497,
CC       ECO:0000269|PubMed:29983246}. Note=Cytosolic under unstressed
CC       conditions: ubiquitinated and degraded by the BCR(KEAP1) E3 ubiquitin
CC       ligase complex (PubMed:15601839, PubMed:21196497). Translocates into
CC       the nucleus upon induction by electrophilic agents that inactivate the
CC       BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:21196497).
CC       {ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16236-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16236-2; Sequence=VSP_025045;
CC       Name=3;
CC         IsoId=Q16236-3; Sequence=VSP_025045, VSP_046168;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest expression in adult
CC       muscle, kidney, lung, liver and in fetal muscle.
CC       {ECO:0000269|PubMed:7937919}.
CC   -!- INDUCTION: Down-regulated by ENC1 via a proteasomal ubiquitin-
CC       independent protein catabolic process. {ECO:0000269|PubMed:19424503}.
CC   -!- DOMAIN: The ETGE motif, and to a lower extent the DLG motif, mediate
CC       interaction with KEAP1. {ECO:0000269|PubMed:15601839}.
CC   -!- PTM: Ubiquitinated in the cytoplasm by the BCR(KEAP1) E3 ubiquitin
CC       ligase complex leading to its degradation (PubMed:15601839,
CC       PubMed:15983046, PubMed:19489739). In response to oxidative stress,
CC       electrophile metabolites, such as sulforaphane, modify KEAP1, leading
CC       to inhibit activity of the BCR(KEAP1) complex, promoting NFE2L2/NRF2
CC       nuclear accumulation and activity (PubMed:19489739, PubMed:29590092).
CC       In response to autophagy, the BCR(KEAP1) complex is inactivated (By
CC       similarity). {ECO:0000250|UniProtKB:Q60795,
CC       ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:15983046,
CC       ECO:0000269|PubMed:19489739, ECO:0000269|PubMed:29590092}.
CC   -!- PTM: Phosphorylated by EIF2AK3/PERK following unfolded protein response
CC       (UPR), promoting dissociation from its cytoplasmic inhibitor KEAP1,
CC       followed by its translocation into the nucleus (By similarity).
CC       Phosphorylation of Ser-40 by PKC in response to oxidative stress
CC       dissociates NFE2L2 from its cytoplasmic inhibitor KEAP1, promoting its
CC       translocation into the nucleus (By similarity).
CC       {ECO:0000250|UniProtKB:O54968, ECO:0000250|UniProtKB:Q60795}.
CC   -!- PTM: Acetylation at Lys-596 and Lys-599 increases nuclear localization
CC       whereas deacetylation by SIRT1 enhances cytoplasmic presence.
CC       {ECO:0000269|PubMed:21196497}.
CC   -!- PTM: Glycation impairs transcription factor activity by preventing
CC       heterodimerization with small Maf proteins (PubMed:31398338).
CC       Deglycation by FN3K restores activity (PubMed:31398338).
CC       {ECO:0000269|PubMed:31398338}.
CC   -!- DISEASE: Immunodeficiency, developmental delay, and hypohomocysteinemia
CC       (IMDDHH) [MIM:617744]: An early onset multisystem disorder
CC       characterized by immunodeficiency, recurrent infections, developmental
CC       delay, poor growth, intellectual disability, and hypohomocysteinemia.
CC       Some patients manifest congenital cardiac defects. IMDDHH inheritance
CC       pattern is autosomal dominant. {ECO:0000269|PubMed:29018201}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the bZIP family. CNC subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB32188.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAD92023.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK304555; BAG65350.1; -; mRNA.
DR   EMBL; AK314816; BAG37339.1; -; mRNA.
DR   EMBL; AB208786; BAD92023.1; ALT_INIT; mRNA.
DR   EMBL; AC019080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079305; AAY14710.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11062.1; -; Genomic_DNA.
DR   EMBL; BC011558; AAH11558.1; -; mRNA.
DR   EMBL; AL135266; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S74017; AAB32188.1; ALT_INIT; mRNA.
DR   CCDS; CCDS42782.1; -. [Q16236-1]
DR   CCDS; CCDS46457.1; -. [Q16236-2]
DR   CCDS; CCDS46458.1; -. [Q16236-3]
DR   RefSeq; NP_001138884.1; NM_001145412.3. [Q16236-2]
DR   RefSeq; NP_001138885.1; NM_001145413.3. [Q16236-3]
DR   RefSeq; NP_001300829.1; NM_001313900.1. [Q16236-2]
DR   RefSeq; NP_001300830.1; NM_001313901.1. [Q16236-2]
DR   RefSeq; NP_006155.2; NM_006164.4. [Q16236-1]
DR   PDB; 2FLU; X-ray; 1.50 A; P=69-84.
DR   PDB; 2LZ1; NMR; -; A=445-523.
DR   PDB; 3ZGC; X-ray; 2.20 A; C=76-82.
DR   PDB; 4IFL; X-ray; 1.80 A; P=69-84.
DR   PDB; 5WFV; X-ray; 1.91 A; P=76-84.
DR   PDB; 6T7V; X-ray; 2.60 A; I=76-84.
DR   PDB; 7K28; X-ray; 2.15 A; P=77-84.
DR   PDB; 7K29; X-ray; 2.20 A; P=76-84.
DR   PDB; 7K2A; X-ray; 1.90 A; P=76-83.
DR   PDB; 7K2B; X-ray; 2.31 A; P=77-83.
DR   PDB; 7K2C; X-ray; 2.11 A; P=77-82.
DR   PDB; 7K2D; X-ray; 2.21 A; P=77-82.
DR   PDB; 7K2E; X-ray; 2.03 A; P=77-82.
DR   PDB; 7K2K; X-ray; 1.98 A; P=77-82.
DR   PDB; 7O7B; NMR; -; A=445-523.
DR   PDB; 7X5E; X-ray; 2.30 A; B/F=452-560.
DR   PDB; 7X5F; X-ray; 2.60 A; B/F=452-560.
DR   PDB; 7X5G; X-ray; 2.30 A; B/F=452-560.
DR   PDB; 8EJR; X-ray; 2.08 A; C=76-82.
DR   PDB; 8EJS; X-ray; 2.82 A; C=76-82.
DR   PDBsum; 2FLU; -.
DR   PDBsum; 2LZ1; -.
DR   PDBsum; 3ZGC; -.
DR   PDBsum; 4IFL; -.
DR   PDBsum; 5WFV; -.
DR   PDBsum; 6T7V; -.
DR   PDBsum; 7K28; -.
DR   PDBsum; 7K29; -.
DR   PDBsum; 7K2A; -.
DR   PDBsum; 7K2B; -.
DR   PDBsum; 7K2C; -.
DR   PDBsum; 7K2D; -.
DR   PDBsum; 7K2E; -.
DR   PDBsum; 7K2K; -.
DR   PDBsum; 7O7B; -.
DR   PDBsum; 7X5E; -.
DR   PDBsum; 7X5F; -.
DR   PDBsum; 7X5G; -.
DR   PDBsum; 8EJR; -.
DR   PDBsum; 8EJS; -.
DR   AlphaFoldDB; Q16236; -.
DR   SMR; Q16236; -.
DR   BioGRID; 110852; 166.
DR   ComplexPortal; CPX-6570; bZIP transcription factor complex, ATF4-NFE2L2.
DR   CORUM; Q16236; -.
DR   DIP; DIP-29971N; -.
DR   ELM; Q16236; -.
DR   FunCoup; Q16236; 3001.
DR   IntAct; Q16236; 131.
DR   MINT; Q16236; -.
DR   STRING; 9606.ENSP00000380252; -.
DR   BindingDB; Q16236; -.
DR   ChEMBL; CHEMBL1075094; -.
DR   DrugBank; DB04339; Carbocisteine.
DR   DrugBank; DB00609; Ethionamide.
DR   DrugBank; DB12513; Omaveloxolone.
DR   DrugBank; DB05650; OT-551.
DR   DrugCentral; Q16236; -.
DR   GlyCosmos; Q16236; 6 sites, No reported glycans.
DR   GlyGen; Q16236; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q16236; -.
DR   PhosphoSitePlus; Q16236; -.
DR   BioMuta; NFE2L2; -.
DR   DMDM; 25453452; -.
DR   jPOST; Q16236; -.
DR   MassIVE; Q16236; -.
DR   PaxDb; 9606-ENSP00000380252; -.
DR   PeptideAtlas; Q16236; -.
DR   ProteomicsDB; 20333; -.
DR   ProteomicsDB; 60843; -. [Q16236-1]
DR   ProteomicsDB; 60844; -. [Q16236-2]
DR   Antibodypedia; 903; 858 antibodies from 45 providers.
DR   DNASU; 4780; -.
DR   Ensembl; ENST00000397062.8; ENSP00000380252.3; ENSG00000116044.17. [Q16236-1]
DR   Ensembl; ENST00000397063.9; ENSP00000380253.4; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000421929.6; ENSP00000412191.2; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000446151.6; ENSP00000411575.2; ENSG00000116044.17. [Q16236-3]
DR   Ensembl; ENST00000448782.6; ENSP00000400073.2; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000464747.5; ENSP00000467401.1; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000699328.1; ENSP00000514303.1; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000699330.1; ENSP00000514304.1; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000699343.1; ENSP00000514318.1; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000699351.1; ENSP00000514325.1; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000699408.1; ENSP00000514369.1; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000699409.1; ENSP00000514370.1; ENSG00000116044.17. [Q16236-2]
DR   Ensembl; ENST00000699434.1; ENSP00000514386.1; ENSG00000116044.17. [Q16236-2]
DR   GeneID; 4780; -.
DR   KEGG; hsa:4780; -.
DR   MANE-Select; ENST00000397062.8; ENSP00000380252.3; NM_006164.5; NP_006155.2.
DR   UCSC; uc002ulg.6; human. [Q16236-1]
DR   AGR; HGNC:7782; -.
DR   CTD; 4780; -.
DR   DisGeNET; 4780; -.
DR   GeneCards; NFE2L2; -.
DR   HGNC; HGNC:7782; NFE2L2.
DR   HPA; ENSG00000116044; Low tissue specificity.
DR   MalaCards; NFE2L2; -.
DR   MIM; 600492; gene.
DR   MIM; 617744; phenotype.
DR   OpenTargets; ENSG00000116044; -.
DR   Orphanet; 619979; Developmental delay-immunodeficiency-leukoencephalopathy-hypohomocysteinemia syndrome.
DR   VEuPathDB; HostDB:ENSG00000116044; -.
DR   eggNOG; KOG3863; Eukaryota.
DR   GeneTree; ENSGT00950000182892; -.
DR   HOGENOM; CLU_498373_0_0_1; -.
DR   InParanoid; Q16236; -.
DR   OMA; DMEEMDQ; -.
DR   OrthoDB; 7458135at2759; -.
DR   PAN-GO; Q16236; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; Q16236; -.
DR   PathwayCommons; Q16236; -.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-9707587; Regulation of HMOX1 expression and activity.
DR   Reactome; R-HSA-9707616; Heme signaling.
DR   Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway.
DR   Reactome; R-HSA-9759194; Nuclear events mediated by NFE2L2.
DR   Reactome; R-HSA-9762114; GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2.
DR   Reactome; R-HSA-9818025; NFE2L2 regulating TCA cycle genes.
DR   Reactome; R-HSA-9818026; NFE2L2 regulating inflammation associated genes.
DR   Reactome; R-HSA-9818027; NFE2L2 regulating anti-oxidant/detoxification enzymes.
DR   Reactome; R-HSA-9818028; NFE2L2 regulates pentose phosphate pathway genes.
DR   Reactome; R-HSA-9818030; NFE2L2 regulating tumorigenic genes.
DR   Reactome; R-HSA-9818032; NFE2L2 regulating MDR associated enzymes.
DR   Reactome; R-HSA-9818035; NFE2L2 regulating ER-stress associated genes.
DR   Reactome; R-HSA-9818749; Regulation of NFE2L2 gene expression.
DR   SignaLink; Q16236; -.
DR   SIGNOR; Q16236; -.
DR   BioGRID-ORCS; 4780; 95 hits in 1196 CRISPR screens.
DR   CD-CODE; 38EC0B30; Transcriptional condensate.
DR   CD-CODE; 5D6181E1; Synthetic Condensate 000293.
DR   CD-CODE; B5B9A610; PML body.
DR   CD-CODE; FBAE0D06; Synthetic Condensate 000291.
DR   ChiTaRS; NFE2L2; human.
DR   EvolutionaryTrace; Q16236; -.
DR   GeneWiki; NFE2L2; -.
DR   GenomeRNAi; 4780; -.
DR   Pharos; Q16236; Tchem.
DR   PRO; PR:Q16236; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q16236; protein.
DR   Bgee; ENSG00000116044; Expressed in epithelium of nasopharynx and 214 other cell types or tissues.
DR   ExpressionAtlas; Q16236; baseline and differential.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0016592; C:mediator complex; EXP:DisProt.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0032993; C:protein-DNA complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ComplexPortal.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB.
DR   GO; GO:0001221; F:transcription coregulator binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:DisProt.
DR   GO; GO:0046223; P:aflatoxin catabolic process; IEA:Ensembl.
DR   GO; GO:0045454; P:cell redox homeostasis; IMP:UniProtKB.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl.
DR   GO; GO:0071280; P:cellular response to copper ion; IEA:Ensembl.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IDA:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IMP:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0061431; P:cellular response to methionine; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProt.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0140467; P:integrated stress response signaling; NAS:ComplexPortal.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:1900038; P:negative regulation of cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0110076; P:negative regulation of ferroptosis; IMP:UniProtKB.
DR   GO; GO:1902037; P:negative regulation of hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0036499; P:PERK-mediated unfolded protein response; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IEA:Ensembl.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:DisProt.
DR   GO; GO:1904294; P:positive regulation of ERAD pathway; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CACAO.
DR   GO; GO:1903788; P:positive regulation of glutathione biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL.
DR   GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010499; P:proteasomal ubiquitin-independent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:1900407; P:regulation of cellular response to oxidative stress; EXP:DisProt.
DR   GO; GO:0045995; P:regulation of embryonic development; IEA:Ensembl.
DR   GO; GO:0045088; P:regulation of innate immune response; ISS:UniProtKB.
DR   GO; GO:2000121; P:regulation of removal of superoxide radicals; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IDA:UniProt.
DR   CDD; cd14720; bZIP_NFE2-like; 1.
DR   CDD; cd22249; UDM1_RNF168_RNF169-like; 1.
DR   DisProt; DP01115; -.
DR   FunFam; 1.10.880.10:FF:000001; Nuclear factor erythroid 2-related factor 2; 1.
DR   Gene3D; 1.10.880.10; Transcription factor, Skn-1-like, DNA-binding domain; 1.
DR   IDEAL; IID00213; -.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR004826; bZIP_Maf.
DR   InterPro; IPR046347; bZIP_sf.
DR   InterPro; IPR047167; NFE2-like.
DR   InterPro; IPR008917; TF_DNA-bd_sf.
DR   PANTHER; PTHR24411; NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR; 1.
DR   PANTHER; PTHR24411:SF3; NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2; 1.
DR   Pfam; PF03131; bZIP_Maf; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF47454; A DNA-binding domain in eukaryotic transcription factors; 1.
DR   SUPFAM; SSF57959; Leucine zipper domain; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
DR   neXtProt; NX_Q16236; -.
DR   PharmGKB; PA31588; -.
DR   TreeFam; TF326681; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm;
KW   Disease variant; DNA-binding; Glycation; Glycoprotein;
KW   Host-virus interaction; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..605
FT                   /note="Nuclear factor erythroid 2-related factor 2"
FT                   /id="PRO_0000076449"
FT   DOMAIN          497..560
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          334..449
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          499..518
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          522..529
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          571..605
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          591..596
FT                   /note="Mediates interaction with CHD6 and is necessary to
FT                   activate transcription"
FT                   /evidence="ECO:0000250|UniProtKB:O54968"
FT   MOTIF           29..31
FT                   /note="DLG motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q60795"
FT   MOTIF           79..82
FT                   /note="ETGE motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q60795"
FT   COMPBIAS        334..354
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        416..430
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        579..588
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         40
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000250|UniProtKB:O54968"
FT   MOD_RES         215
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         596
FT                   /note="N6-acetyllysine; by CREBBP"
FT                   /evidence="ECO:0000269|PubMed:21196497"
FT   MOD_RES         599
FT                   /note="N6-acetyllysine; by CREBBP"
FT                   /evidence="ECO:0000269|PubMed:21196497"
FT   CARBOHYD        462
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CARBOHYD        472
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CARBOHYD        487
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CARBOHYD        499
FT                   /note="N-linked (Glc) (glycation) arginine"
FT                   /evidence="ECO:0000305|PubMed:31398338"
FT   CARBOHYD        569
FT                   /note="N-linked (Glc) (glycation) arginine"
FT                   /evidence="ECO:0000305|PubMed:31398338"
FT   CARBOHYD        574
FT                   /note="N-linked (Glc) (glycation) lysine"
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   VAR_SEQ         1..16
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.2"
FT                   /id="VSP_025045"
FT   VAR_SEQ         135..141
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046168"
FT   VARIANT         31
FT                   /note="G -> R (in IMDDHH; dbSNP:rs1553488015)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080492"
FT   VARIANT         43
FT                   /note="R -> Q (in dbSNP:rs35248500)"
FT                   /id="VAR_032110"
FT   VARIANT         79
FT                   /note="E -> K (in IMDDHH; dbSNP:rs1057519922)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080493"
FT   VARIANT         80
FT                   /note="T -> K (in IMDDHH; increased protein abundance;
FT                   increased positive regulation of transcription of target
FT                   genes; changed cell redox homeostasis; dbSNP:rs1553487947)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080494"
FT   VARIANT         81
FT                   /note="G -> S (in IMDDHH; dbSNP:rs1553487942)"
FT                   /evidence="ECO:0000269|PubMed:29018201"
FT                   /id="VAR_080495"
FT   VARIANT         99
FT                   /note="S -> P (in dbSNP:rs5031039)"
FT                   /id="VAR_020322"
FT   VARIANT         268
FT                   /note="V -> M (in dbSNP:rs34154613)"
FT                   /id="VAR_032111"
FT   MUTAGEN         79..82
FT                   /note="Missing: Abolished interaction with KEAP1."
FT                   /evidence="ECO:0000269|PubMed:15601839"
FT   MUTAGEN         80
FT                   /note="T->A: Loss of interaction with KEAP1."
FT                   /evidence="ECO:0000269|PubMed:16888629"
FT   MUTAGEN         82
FT                   /note="E->G: Abolished interaction with KEAP1."
FT                   /evidence="ECO:0000269|PubMed:15601839"
FT   MUTAGEN         462
FT                   /note="K->A: Loss of function; when associated with A-472;
FT                   A-487; A-499; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         472
FT                   /note="K->A: Loss of function; when associated with A-462;
FT                   A-487; A-499; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         487
FT                   /note="K->A: Loss of function; when associated with A-462;
FT                   A-472; A-499; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         499
FT                   /note="R->A: Loss of function; when associated with A-462;
FT                   A-472; A-487; A-569 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         569
FT                   /note="R->A: Loss of function; when associated with A-462;
FT                   A-472; A-487; A-499 and A-587."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   MUTAGEN         587
FT                   /note="R->A: Loss of function; when associated with A-462;
FT                   A-472; A-487; A-499 and A-569."
FT                   /evidence="ECO:0000269|PubMed:31398338"
FT   CONFLICT        72
FT                   /note="A -> T (in Ref. 7; AAB32188)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        92
FT                   /note="I -> T (in Ref. 7; AAB32188)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        178
FT                   /note="D -> Y (in Ref. 3; AL135266)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        521
FT                   /note="N -> D (in Ref. 1; BAG65350)"
FT                   /evidence="ECO:0000305"
FT   TURN            78..80
FT                   /evidence="ECO:0007829|PDB:2FLU"
FT   STRAND          449..455
FT                   /evidence="ECO:0007829|PDB:7O7B"
FT   HELIX           456..463
FT                   /evidence="ECO:0007829|PDB:7X5E"
FT   HELIX           470..475
FT                   /evidence="ECO:0007829|PDB:7X5E"
FT   HELIX           478..485
FT                   /evidence="ECO:0007829|PDB:7X5E"
FT   HELIX           492..556
FT                   /evidence="ECO:0007829|PDB:7X5E"
SQ   SEQUENCE   605 AA;  67827 MW;  99FAFD811B6C1416 CRC64;
     MMDLELPPPG LPSQQDMDLI DILWRQDIDL GVSREVFDFS QRRKEYELEK QKKLEKERQE
     QLQKEQEKAF FAQLQLDEET GEFLPIQPAQ HIQSETSGSA NYSQVAHIPK SDALYFDDCM
     QLLAQTFPFV DDNEVSSATF QSLVPDIPGH IESPVFIATN QAQSPETSVA QVAPVDLDGM
     QQDIEQVWEE LLSIPELQCL NIENDKLVET TMVPSPEAKL TEVDNYHFYS SIPSMEKEVG
     NCSPHFLNAF EDSFSSILST EDPNQLTVNS LNSDATVNTD FGDEFYSAFI AEPSISNSMP
     SPATLSHSLS ELLNGPIDVS DLSLCKAFNQ NHPESTAEFN DSDSGISLNT SPSVASPEHS
     VESSSYGDTL LGLSDSEVEE LDSAPGSVKQ NGPKTPVHSS GDMVQPLSPS QGQSTHVHDA
     QCENTPEKEL PVSPGHRKTP FTKDKHSSRL EAHLTRDELR AKALHIPFPV EKIINLPVVD
     FNEMMSKEQF NEAQLALIRD IRRRGKNKVA AQNCRKRKLE NIVELEQDLD HLKDEKEKLL
     KEKGENDKSL HLLKKQLSTL YLEVFSMLRD EDGKPYSPSE YSLQQTRDGN VFLVPKSKKP
     DVKKN
//
